loadpatents
Patent applications and USPTO patent grants for Blumberg; Richard S..The latest application filed is for "use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases".
Patent | Date |
---|---|
Use Of Anti-fcrn Antibodies In The Treatment Of Pemphighus And Pemphigoid Diseases App 20220298241 - Blumberg; Laurence J. ;   et al. | 2022-09-22 |
Humanized and Affinity-Matured Anti-CEACAM1 Antibodies App 20220025040 - Blumberg; Richard S. ;   et al. | 2022-01-27 |
Compositions And Methods For Modulating An Immune Response App 20210347887 - Blumberg; Richard S. ;   et al. | 2021-11-11 |
Therapeutic Fcrn-based Bispecific Monoclonal Antibodies App 20210139582 - BLUMBERG; Richard S. ;   et al. | 2021-05-13 |
Therapeutic And Immunomodulatory Bacteriophage Formulations And Methods For Making And Using Them App 20210062160 - ROHWER; Forest ;   et al. | 2021-03-04 |
Oxazole Containing Compounds As Activators Of Ido1 And Ahr App 20210009535 - BLUMBERG; Richard S. ;   et al. | 2021-01-14 |
Humanized affinity matured anti-FcRn antibodies Grant 10,822,417 - Blumberg , et al. November 3, 2 | 2020-11-03 |
Compositions And Methods For Treating Subjects With Immune-mediated Diseases App 20200241001 - BLUMBERG; Richard S. ;   et al. | 2020-07-30 |
HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES App 20200207854 - Blumberg; Laurence J. ;   et al. | 2020-07-02 |
HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES App 20200181262 - Blumberg; Laurence J. ;   et al. | 2020-06-11 |
Humanized affinity matured anti-FcRn antibodies Grant 10,626,175 - Blumberg , et al. | 2020-04-21 |
Modulation Of The Immune Response App 20200095284 - BLUMBERG; RICHARD S. ;   et al. | 2020-03-26 |
FC receptor (FcRn) binding peptides and uses thereof Grant 10,588,935 - Blumberg , et al. | 2020-03-17 |
Compositions And Methods For Modulating An Immune Response App 20200040076 - Blumberg; Richard S. ;   et al. | 2020-02-06 |
Methods To Manipulate Alpha-fetoprotein (afp) App 20200031928 - BLUMBERG; Richard S. ;   et al. | 2020-01-30 |
Compositions And Methods For Modulating An Immune Response App 20200024343 - Blumberg; Richard S. ;   et al. | 2020-01-23 |
FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF App 20200023034 - Blumberg; Richard S. ;   et al. | 2020-01-23 |
Methods To Manipulate Alpha-fetoprotein (afp) App 20200010543 - BLUMBERG; Richard S. ;   et al. | 2020-01-09 |
Modulation of the immune response Grant 10,513,540 - Blumberg , et al. Dec | 2019-12-24 |
Targeting Oxazole Structures For Therapy Against Inflammatory Diseases App 20190225683 - BLUMBERG; Richard S. ;   et al. | 2019-07-25 |
Enhancement Of The Immune Response App 20190201524 - BLUMBERG; Richard S. ;   et al. | 2019-07-04 |
Blockade Of Alphafetoprotein (afp) Interactions With Beta2-microglobulin Associated Molecules App 20190201496 - BLUMBERG; Richard S. ;   et al. | 2019-07-04 |
Glycosphingolipids and methods of use thereof Grant 10,329,315 - Kasper , et al. | 2019-06-25 |
FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF App 20190183964 - BLUMBERG; Richard S. ;   et al. | 2019-06-20 |
Compositions And Methods For Modulating An Immune Response App 20190169290 - Blumberg; Richard S. ;   et al. | 2019-06-06 |
HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES App 20190135915 - Blumberg; Laurence J. ;   et al. | 2019-05-09 |
Interactions Between Ceacam And Tim Family Members App 20180298095 - BLUMBERG; Richard S. ;   et al. | 2018-10-18 |
HUMAZNIZED AFFINITY MATURED ANIT-FcRn ANTIBODIES App 20180291101 - Blumberg; Laurence J. ;   et al. | 2018-10-11 |
FC receptor (FcRn) binding peptides and uses thereof Grant 10,046,023 - Blumberg , et al. August 14, 2 | 2018-08-14 |
Compositions and methods for modulating an immune response Grant 10,035,858 - Blumberg , et al. July 31, 2 | 2018-07-31 |
Interactions Between Ceacam And Tim Family Members App 20180153986 - BLUMBERG; Richard S. ;   et al. | 2018-06-07 |
Receptor-targeted Nanoparticles For Enhanced Transcytosis Mediated Drug Delivery App 20180021455 - Pridgen; Eric M. ;   et al. | 2018-01-25 |
Anti-ceacam1 Recombinant Antibodies For Cancer Therapy App 20170327578 - BLUMBERG; Richard S. ;   et al. | 2017-11-16 |
FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF App 20170209529 - BLUMBERG; Richard S. ;   et al. | 2017-07-27 |
Assays and methods to sequence microbes directly from immune complexes Grant 9,689,044 - Blumberg , et al. June 27, 2 | 2017-06-27 |
Methods To Manipulate Alpha-fetoprotein (afp) App 20170044257 - BLUMBERG; Richard S. ;   et al. | 2017-02-16 |
Compositions And Methods For Treating Subjects With Immune-mediated Diseases App 20170045528 - BLUMBERG; Richard S. ;   et al. | 2017-02-16 |
Anti-CEACAM1 recombinant antibodies for cancer therapy Grant 9,556,271 - Blumberg , et al. January 31, 2 | 2017-01-31 |
Receptor-targeted Nanoparticles For Enhanced Transcytosis Mediated Drug Delivery App 20170000899 - Pridgen; Eric M. ;   et al. | 2017-01-05 |
Compositions And Methods For Modulating An Immune Response App 20170002073 - Blumberg; Richard S. ;   et al. | 2017-01-05 |
FC receptor (FcRn) binding peptides and uses thereof Grant 9,527,890 - Blumberg , et al. December 27, 2 | 2016-12-27 |
FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF App 20160122394 - BLUMBERG; Richard S. ;   et al. | 2016-05-05 |
Enhancement Of The Immune Response App 20150273056 - Blumberg; Richard S ;   et al. | 2015-10-01 |
Glycosphingolipids And Methods Of Use Thereof App 20150252068 - Kasper; Dennis L. ;   et al. | 2015-09-10 |
Modulation Of The Immune Response App 20150225457 - Blumberg; Richard S. ;   et al. | 2015-08-13 |
Anti-ceacam1 Recombinant Antibodies For Cancer Therapy App 20140328841 - Blumberg; Richard S. ;   et al. | 2014-11-06 |
Methods of treating and preventing colitis involving IL-13 and NK-T cells Grant 8,821,866 - Strober , et al. September 2, 2 | 2014-09-02 |
Assays And Methods To Sequence Microbes Directly From Immune Complexes App 20130330715 - Blumberg; Richard S. ;   et al. | 2013-12-12 |
Methods Of Treating And Preventing Colitis Involving Il-13 And Nk-t Cells App 20120276113 - Strober; Warren ;   et al. | 2012-11-01 |
Disrupting FCRN-albumin interactions Grant 8,232,067 - Blumberg , et al. July 31, 2 | 2012-07-31 |
T Cell Inhibitory Receptor Compositions And Uses Thereof App 20120141470 - Blumberg; Richard S. | 2012-06-07 |
Disrupting FCRN-Albumin Interactions App 20120107845 - Blumberg; Richard S. ;   et al. | 2012-05-03 |
T cell inhibitory receptor compositions and uses thereof Grant 8,110,189 - Blumberg February 7, 2 | 2012-02-07 |
Methods Of Treating And Preventing Colitis Involving Il-13 And Nk-t Cells App 20100143339 - Strober; Warren ;   et al. | 2010-06-10 |
Methods of treating and preventing colitis involving IL-13 and NK-T cells Grant 7,666,411 - Strober , et al. February 23, 2 | 2010-02-23 |
Receptor specific transepithelial transport of therapeutics Grant 7,547,436 - Blumberg , et al. June 16, 2 | 2009-06-16 |
T cell inhibitory receptor compositions and uses thereof App 20080102071 - Blumberg; Richard S. | 2008-05-01 |
Receptor specific transepithelial transport of therapeutics App 20070020192 - Blumberg; Richard S. ;   et al. | 2007-01-25 |
Identification of compounds that bind biliary glycoprotein and affect cytotoxic T lymphocyte activity Grant 7,132,255 - Blumberg November 7, 2 | 2006-11-07 |
Central airway administration for systemic delivery of therapeutics App 20060140907 - Blumberg; Richard S. ;   et al. | 2006-06-29 |
Receptor specific transepithelial transport in therapeutics Grant 7,067,129 - Blumberg , et al. June 27, 2 | 2006-06-27 |
Receptor specific transepithelial transport of therapeutics Grant 7,060,274 - Blumberg , et al. June 13, 2 | 2006-06-13 |
Methods of treating and preventing colitis involving il-13 and nk-t cells App 20060024306 - Strober; Warren ;   et al. | 2006-02-02 |
Methods of inhibiting inflammation App 20050234073 - Blumberg, Richard S. | 2005-10-20 |
T cell inhibitory receptor compositions and uses thereof App 20050169922 - Blumberg, Richard S. | 2005-08-04 |
Methods of inhibiting inflammation App 20050090426 - Blumberg, Richard S. | 2005-04-28 |
T cell inhibitory receptor compositions and uses thereof Grant 6,852,320 - Blumberg February 8, 2 | 2005-02-08 |
Central airway administration for systemic delivery of therapeutics App 20040063912 - Blumberg, Richard S. ;   et al. | 2004-04-01 |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof App 20040047858 - Blumberg, Richard S. ;   et al. | 2004-03-11 |
Central airway administration for systemic delivery of therapeutics App 20030235536 - Blumberg, Richard S. ;   et al. | 2003-12-25 |
Receptor specific transepithelial transport of therapeutics App 20030012789 - Blumberg, Richard S. ;   et al. | 2003-01-16 |
Receptor specific transepithelial transport of therapeutics App 20020192222 - Blumberg, Richard S. ;   et al. | 2002-12-19 |
Receptor specific transepithelial transport of therapeutics Grant 6,485,726 - Blumberg , et al. November 26, 2 | 2002-11-26 |
T cell inhibitory receptor compositions and uses thereof App 20020028203 - Blumberg, Richard S. | 2002-03-07 |
Receptor specific transepithelial transport of immunogens Grant 6,086,875 - Blumberg , et al. July 11, 2 | 2000-07-11 |
Receptor specific transepithelial transport of therapeutics Grant 6,030,613 - Blumberg , et al. February 29, 2 | 2000-02-29 |
NCAGE Code | 6CHJ4 | BLUMBERG RICHARD S |
CAGE Code | 6CHJ4 | BLUMBERG RICHARD S |
DUNS | 623827909 | BLUMBERG, RICHARD S |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.